Spots Global Cancer Trial Database for Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment

Official Title: Incidence and Risk Factors for Invasive Mold Infections in Children During First-Line Chemotherapy for Primary Acute Leukemia: Protocol for a National Retrospective Cohort Study

Study ID: NCT05774990

Conditions

Leukemia, Myeloid, Acute

Acute Lymphoblastic Leukemia

Interventions

Study Description

Brief Summary: The study aims to evaluate the occurrence, mortality, and risk factors for invasive mold infections (IMI) in children treated with chemotherapy for acute leukemia in Denmark. The study will be a retrospective nationwide survey study of all children who received first-line chemotherapy for acute leukemia from 2008 to 2022 in Danish pediatric oncology units. The study population will include approximately 800 children under the age of 18. Data will be collected from medical records, hospital databases, and national databases. When the IMI subgroup has been identified, this will be compared to the leukemic group that did not develop IMI. Statistical analysis can then determine the occurrence, mortality rate, and possible IMI risk factors.

Detailed Description: Chemotherapy can weaken children's immune system, making them vulnerable to infections, including invasive mold infections (IMI), caused mainly by Aspergillus spp. The at-risk population for IMI in children with acquired immunodeficiency is patients with prolonged granulocytopenia due to hematologic malignancies treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT) recipients and children receiving long-term corticosteroid treatment. Incidences and mortality rates are often reported as high. In a retrospective cohort study, we aim to obtain an epidemiological overview of IMI in children receiving first-line treatment for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) in Denmark from 2008 to 2022 and identify possible risk factors, including treatment-related adverse effects. Objectives 1. To determine and compare the incidence of IMI in childhood AML and ALL during first-line chemotherapy in Denmark. 2. To determine and compare the mortality of IMI in childhood AML and ALL during first-line chemotherapy in Denmark. 3. To explore risk factors for IMI in childhood AML and ALL during first-line chemotherapy in Denmark.